Patents by Inventor Michael Robert West

Michael Robert West has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • IMMUNOGLOBULINS
    Publication number: 20110245470
    Abstract: The present invention concerns immunoglobulins, such as antibodies, which specifically bind Oncostatin M (OSM), particularly human OSM (hOSM) and modulate the interaction between OSM and gp130. In typical embodiments, OSM is glycosylated. The invention also concerns antibodies that modulate the interaction between both Site II and Site III of OSM and their respective interacting partners. Further disclosed are pharmaceutical compositions, screening and medical treatment methods.
    Type: Application
    Filed: November 16, 2010
    Publication date: October 6, 2011
    Inventors: Jonathan Henry ELLIS, Alexandre EON-DUVAL, Volker GERMASCHEWSKI, Christopher PLUMPTON, Nicholas Timothy RAPSON, Michael Robert WEST
  • Immunoglobulins
    Patent number: 7858753
    Abstract: The present invention concerns immunoglobulins, such as antibodies, which specifically bind Oncostatin M (OSM), particularly human OSM (hOSM) and modulate the interaction between OSM and gp130. In typical embodiments, OSM is glycosylated. The invention also concerns antibodies that modulate the interaction between both Site II and Site III of OSM and their respective interacting partners. Further disclosed are pharmaceutical compositions, screening and medical treatment methods.
    Type: Grant
    Filed: March 29, 2005
    Date of Patent: December 28, 2010
    Assignee: Glaxo Group Limited
    Inventors: Jonathan Henry Ellis, Alexandre Eon-Duval, Volker Germaschewski, Christopher Plumpton, Nicholas Timothy Rapson, Michael Robert West
  • Diagnosis of chronic obstructive pulmonary disease
    Patent number: 6929920
    Abstract: Methods of determining Chronic Obstructive Pulmonary Disease (COPD) severity in patients which comprises measuring the concentration of soluble E-cadherin (sE-cadherin) in the patient's urine and/or blood serum and determining the extent of severity by reference to correlation graphs, a method of treating patients with COPD, methods for determining the responsiveness of said patients to said treatment and a prognostic product for detecting the concentration of sE-cadherin in urine and/or blood serum.
    Type: Grant
    Filed: May 25, 2000
    Date of Patent: August 16, 2005
    Assignee: Glaxo Group Limited
    Inventor: Michael Robert West
  • Use of fluticasone propionate in the treatment of diseases ameliorated by enhancement of epithelial madrix adhesion such as asthma cystic fibrosis and influenza
    Publication number: 20040132700
    Abstract: The invention relates to the use of corticosteroids and fluitcasone propionate in particular for the treatment of diseases which may be ameliorated by enhancement of epithelium/matrix adhesion.
    Type: Application
    Filed: February 20, 2004
    Publication date: July 8, 2004
    Inventors: Joyce Lesley Matthews, Michael Robert West